GLP-1 Drugs for Gestational Diabetes: Emerging Evidence and Considerations
Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease.
Quick Facts
What This Study Found
Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease.
Key Numbers
Review identified trials testing three specific GLP-1 drugs (liraglutide, semaglutide, exenatide) for gestational diabetes from ClinicalTrials.gov.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide therapeutic knowledge.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Comparison to evidence?
- ?Next research?
Trust & Context
- Key Stat:
- Key finding Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety con
- Evidence Grade:
- Based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
- Published In:
- Medicine, 104(40), e44917 (2025)
- Authors:
- Alshehri, Fahad S(2)
- Database ID:
- RPEP-09906
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of GLP-1 agonist developments for gestational diabetes explores efficacy evidence, safety concerns, and the potential role of these drugs in pregnancy-related metabolic disease.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09906APA
Alshehri, Fahad S. (2025). New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.. Medicine, 104(40), e44917. https://doi.org/10.1097/MD.0000000000044917
MLA
Alshehri, Fahad S. "New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.." Medicine, 2025. https://doi.org/10.1097/MD.0000000000044917
RethinkPeptides
RethinkPeptides Research Database. "New developments in GLP-1 agonist therapy for gestational di..." RPEP-09906. Retrieved from https://rethinkpeptides.com/research/alshehri-2025-new-developments-in-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.